126 related articles for article (PubMed ID: 10390891)
1. [Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease].
Uno S; Katayama K; Dobashi N; Hirano A; Ogihara A; Yamazaki H; Usui N; Kobayashi T; Inoue K; Kuraishi Y
Rinsho Ketsueki; 1999 May; 40(5):414-9. PubMed ID: 10390891
[TBL] [Abstract][Full Text] [Related]
2. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Nishikawa T; Kawakami K; Kumamoto T; Tonooka S; Abe A; Hayasaka K; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2008 Jul; 30(7):519-21. PubMed ID: 18797198
[TBL] [Abstract][Full Text] [Related]
3. Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor.
Schiavetti A; Frascarelli M; Uccini S; Novelli A
Pediatr Blood Cancer; 2004 Oct; 43(5):606-9. PubMed ID: 15382281
[TBL] [Abstract][Full Text] [Related]
4. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.
Hildebrandt G; Holler E; Woenkhaus M; Quarch G; Reichle A; Schalke B; Andreesen R
Ann Oncol; 2000 Jun; 11(6):743-7. PubMed ID: 10942065
[TBL] [Abstract][Full Text] [Related]
5. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.
Neumann Y; Toren A; Rechavi G; Seifried B; Shoham NG; Mandel M; Kenet G; Sharon N; Sadeh M; Navon R
Med Pediatr Oncol; 1996 Apr; 26(4):280-3. PubMed ID: 8600343
[TBL] [Abstract][Full Text] [Related]
6. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome.
Hogan-Dann CM; Fellmeth WG; McGuire SA; Kiley VA
JAMA; 1984 Nov 23-30; 252(20):2862-3. PubMed ID: 6092732
[TBL] [Abstract][Full Text] [Related]
7. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.
Ichikawa M; Suzuki D; Inamoto J; Ohshima J; Cho Y; Saitoh S; Kaneda M; Iguchi A; Ariga T
J Pediatr Hematol Oncol; 2012 Apr; 34(3):239-41. PubMed ID: 22246157
[TBL] [Abstract][Full Text] [Related]
8. [A case of Charcot-Marie-Tooth disease (CMT) type 1 complicated by diabetes mellitus (DM) showing bilateral phrenic nerve palsy].
Takakura Y; Furuya H; Yamashita K; Murai H; Araki T; Kikuchi H; Ohyagi Y; Yamada T; Kira J
Rinsho Shinkeigaku; 2002 Apr; 42(4):320-2. PubMed ID: 12561089
[TBL] [Abstract][Full Text] [Related]
9. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
10. [A case of hereditary motor and sensory neuropathy with vocal cords palsy and diaphragmatic weakness].
Fukuda H; Kitani M; Imaoka K
Rinsho Shinkeigaku; 1993 Feb; 33(2):175-81. PubMed ID: 8319389
[TBL] [Abstract][Full Text] [Related]
11. Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
Sun XF; Zhen ZJ; Lui DG; Xia Y; He YJ; Wang ZH; Lin JY; Guan ZZ
Eur J Haematol; 2006 Nov; 77(5):365-71. PubMed ID: 16879606
[TBL] [Abstract][Full Text] [Related]
12. Vincristine neurotoxicity in Charcot-Marie-Tooth syndrome.
Griffiths JD; Stark RJ; Ding JC; Cooper IA
Med J Aust; 1985 Sep; 143(7):305-6. PubMed ID: 4046919
[TBL] [Abstract][Full Text] [Related]
13. Successfully-treated mesenteric non-Hodgkin's lymphoma involving hepatic mass--a case report.
Yamaguchi T; Takahashi H; Kagawa R; Takeda R; Sakata S; Yamamoto M; Nishizaki D; Takamatsu T; Iwasa Y
Gan To Kagaku Ryoho; 2007 May; 34(5):783-7. PubMed ID: 17496458
[TBL] [Abstract][Full Text] [Related]
14. [A pedigree of Charcot-Marie-Tooth disease type 4F (Periaxin mutation)].
Shimohata M; Hirahara K; Igarashi S; Hara K; Kijima K; Onodera O; Tanaka K; Nishizawa M; Tsuji S; Hayasaka K
Rinsho Shinkeigaku; 2005 Mar; 45(3):221-5. PubMed ID: 15835292
[TBL] [Abstract][Full Text] [Related]
15. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
16. [Therapy-related acute myeloid leukemia following double autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma].
Fujii H; Iwai T; Ueda Y; Nakagawa H
Rinsho Ketsueki; 2002 Jun; 43(6):482-7. PubMed ID: 12134706
[TBL] [Abstract][Full Text] [Related]
17. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
Bai CM; Yang T; Xü Y; Zhang W; Liu XL; Zhu YL; Chen SC; Shen T
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):142-4. PubMed ID: 16750023
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.
Kornacker M; Kraemer A; Leo E; Ho AD
Ann Hematol; 2002 Feb; 81(2):103-5. PubMed ID: 11907791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
